Mylan Launches Advair Rival In Canada
Firm’s Wixela Inhub Version Is First Rival To GSK Brand
Mylan has rolled out the first generic rival to GlaxoSmithKline’s Advair in Canada with the launch of its Wixela Inhub version.
You may also be interested in...
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.
Mylan says its ‘durable’ business model has helped it to withstand pressures from adverse industry trends in 2019, boosted by $1bn in sales from newly-launched products. However, negative currency effects cut the firm’s sales growth from 3% at constant currencies to 1% as reported.
Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.